{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:31:23Z","timestamp":1775669483399,"version":"3.50.1"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Hosp Pharm"],"abstract":"<jats:p>Background: Hypomagnesemia, characterized by decreased levels of magnesium in the blood, is common among patients with cancer and may be related to the administration of proton pump inhibitors (PPIs) and\/or platinum derivatives.\nObjective: To evaluate the safety and potential impact on serum magnesium levels of concomitant use of the PPI omeprazole in patients receiving a platinum derivative.\nMethods: This prospective, randomized, double-blind, single-dose, placebo-controlled study involved fixed doses of PPI administered on an outpatient basis. It spanned 4 cycles of platinum-based combination chemotherapy (21 days per cycle), and entailed a screening period (14 days before chemotherapy), 2 PPI treatment periods (total of 60 days), and a follow-up period (1 cycle). Patients recruited between May 2019 and March 2020 at 3 hospitals in Brazil were randomly assigned to receive placebo or PPI in a 1:1 ratio. Data analysis employed a linear mixed-effects model and Kaplan\u2013Meier analysis.\nResults: A total of 164 patients were included in the study, 83 in the placebo group and 81 in the PPI group. Blood magnesium levels showed a modest decrease over time (by approximately 20%) across all patients. A correlation was observed between treatment duration and decrease in serum magnesium in the total sample (\u03b2 = \u20130.035, 95% confidence interval [CI] \u20130.048 to \u20130.0021; p &lt; 0.001). Compared with the placebo group, the PPI group showed a slightly greater decline (\u03b2 = \u20130.121, 95% CI \u20130.231 to \u20130.011; p = 0.031). Additionally, no differences were noted between groups regarding the occurrence of neuropathy (p = 0.77), anorexia (p = 0.77), diarrhea (p = 0.34), or constipation (p = 0.39). Omeprazole use was associated with a lower incidence of nausea and vomiting (p = 0.005).\nConclusion: These exploratory findings suggest that the concomitant use of omeprazole with platinum derivatives may be associated with a slightly faster rate of serum magnesium depletion than occurs with chemotherapy alone, but without clinical relevance or occurrence of frank hypomagnesemia.\nKeywords: magnesium, clinical oncology, platinum compounds, proton pump inhibitors, adverse effects\nClinical trial registration: Brazilian Registry of Clinical Trials (ReBEC) RBR-8vsb7k2\nR\u00c9SUM\u00c9\nContexte : L\u2019hypomagn\u00e9s\u00e9mie se caract\u00e9rise par une r\u00e9duction des taux de magn\u00e9sium dans le sang. Elle est r\u00e9pandue chez les patients atteints d\u2019un cancer et peut \u00eatre li\u00e9e \u00e0 l\u2019administration d\u2019inhibiteurs de la pompe \u00e0 protons (IPP) et\/ou de d\u00e9riv\u00e9s du platine.\nObjectif : \u00c9valuer l\u2019innocuit\u00e9 et l\u2019incidence potentielle sur les taux s\u00e9riques de magn\u00e9sium de l\u2019utilisation concomitante de l\u2019IPP om\u00e9prazole chez des patients recevant un d\u00e9riv\u00e9 du platine.\nM\u00e9thodologie : Cette \u00e9tude prospective, randomis\u00e9e, \u00e0 double insu, \u00e0 dose unique et contr\u00f4l\u00e9e par placebo portait sur des doses fixes d\u2019IPP administr\u00e9es en ambulatoire. Elle s\u2019est d\u00e9roul\u00e9e pendant 4 cycles de chimioth\u00e9rapie combin\u00e9e \u00e0 base de platine (21 jours par cycle) et comprenait une p\u00e9riode de s\u00e9lection (14 jours avant la chimioth\u00e9rapie), deux p\u00e9riodes de traitement \u00e0 l\u2019IPP (comprenant 60 jours au total) et une p\u00e9riode de suivi (1 cycle). Des patients recrut\u00e9s dans 3 h\u00f4pitaux du Br\u00e9sil entre mai 2019 et mars 2020 ont \u00e9t\u00e9 r\u00e9partis de mani\u00e8re al\u00e9atoire pour recevoir soit un placebo, soit un IPP, selon un ratio de 1:1. Un mod\u00e8le lin\u00e9aire \u00e0 effets mixtes ainsi qu\u2019une analyse de Kaplan-Meier ont \u00e9t\u00e9 utilis\u00e9s pour l\u2019analyse des donn\u00e9es.\nR\u00e9sultats : Au total, 164 patients ont \u00e9t\u00e9 inclus dans l\u2019\u00e9tude : 83 dans le groupe placebo et 81 dans le groupe IPP. Une diminution modeste avec le temps (environ 20 %) des taux sanguins de magn\u00e9sium chez l\u2019ensemble des patients a \u00e9t\u00e9 constat\u00e9e. Une corr\u00e9lation a \u00e9t\u00e9 observ\u00e9e entre la dur\u00e9e du traitement et la diminution du magn\u00e9sium s\u00e9rique chez l\u2019ensemble des patients (\u03b2 = \u20130,035; intervalle de confiance [IC] \u00e0 95 % : \u20130,048 \u00e0 \u20130,002 1; p &lt; 0,001). Cette diminution \u00e9tait l\u00e9g\u00e8rement plus marqu\u00e9e dans le groupe IPP que dans le groupe placebo (\u03b2 = \u20130,121; IC \u00e0 95 % : \u20130,231 \u00e0 \u20130,011; p = 0,031). De plus, aucune diff\u00e9rence n\u2019a \u00e9t\u00e9 observ\u00e9e entre les groupes concernant la survenuede neuropathie (p = 0,77), d\u2019anorexie (p = 0,77), de diarrh\u00e9e (p = 0,34) ou de constipation p = 0,39). L\u2019utilisation de l\u2019om\u00e9prazole \u00e9tait associ\u00e9e \u00e0 une incidence plus faible de naus\u00e9es et de vomissements (p = 0,005).\nConclusion : Ces r\u00e9sultats exploratoires indiquent que l\u2019utilisation concomitante de l\u2019om\u00e9prazole avec des d\u00e9riv\u00e9s du platine pourrait \u00eatre associ\u00e9e \u00e0 une diminution l\u00e9g\u00e8rement plus rapide des taux s\u00e9riques de magn\u00e9siumque celle observ\u00e9e avec la chimioth\u00e9rapie seule, sans toutefois pr\u00e9senter de pertinence clinique ni entra\u00eener la survenue d\u2019une hypomagn\u00e9s\u00e9mie franche.\nMots-cl\u00e9s : magn\u00e9sium, oncologie clinique, compos\u00e9s du platine, inhibiteurs de la pompe \u00e0 protons, effets ind\u00e9sirables\nInscription \u00e0 l\u2019essai clinique : Brazilian Registry of Clinical Trials (ReBEC) RBR-8vsb7k2<\/jats:p>","DOI":"10.4212\/cjhp.3600","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:40:24Z","timestamp":1775666424000},"source":"Crossref","is-referenced-by-count":0,"title":["Hypomagnesemia Associated with Omeprazole Use in Patients Treated with Platinum Derivatives: An Exploratory Randomized Placebo-Controlled Clinical Trial"],"prefix":"10.4212","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1792-3672","authenticated-orcid":false,"given":"Ney Moura","family":"Lemos Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9668-0482","authenticated-orcid":false,"given":"Rand Randall","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7118-2145","authenticated-orcid":false,"given":"Telma Maria","family":"Ara\u00fajo Moura Lemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7002-947X","authenticated-orcid":false,"given":"Andr\u00e9a Carla","family":"Pinto Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7388-663X","authenticated-orcid":false,"given":"Andr\u00e9a Juliana","family":"Pereira Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5727-3091","authenticated-orcid":false,"given":"Marcos","family":"Dias Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-599X","authenticated-orcid":false,"given":"Priscilla Karilline","family":"Do Vale Bezerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-6532","authenticated-orcid":false,"given":"Antonio","family":"Gouveia Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-4485","authenticated-orcid":false,"given":"Fernanda","family":"Nervo Raffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2732","published-online":{"date-parts":[[2026,4,8]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3600\/5859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3600\/5863","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3600\/5859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:40:25Z","timestamp":1775666425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,8]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3600","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"article-number":"e3600"}}